Literature DB >> 321170

The therapeutic equivalence of oral and intravenous iron in renal dialysis patients.

I D Strickland, D M Chaput de Saintonge, F E Boulton, B Francis, J Roubikova, J I Waters.   

Abstract

Oral and intravenous iron were compared in patients treated with renal dialysis by a cross-over trial. Intravenous iron was given over 2 weeks as an iron dextran (equivalent to 100 mg elemental iron). Oral iron was given daily as ferrous sulphate (equivalent to 100 mg elemental iron) in a wax matrix tablet. Each treatment period lasted 26 weeks. There was no significant difference in therapeutic or unwanted effects between the treatments.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 321170

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  6 in total

1.  Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm.

Authors:  I C Macdougall; R D Hutton; I Cavill; G A Coles; J D Williams
Journal:  BMJ       Date:  1990-03-10

Review 2.  The use of erythropoietin in renal failure.

Authors:  I C Macdougall; R D Hutton; G A Coles; J D Williams
Journal:  Postgrad Med J       Date:  1991-01       Impact factor: 2.401

3.  When can 'non significantly different' treatments be considered as 'equivalent'?

Authors:  A Spriet; D Beiler
Journal:  Br J Clin Pharmacol       Date:  1979-06       Impact factor: 4.335

4.  Parenteral versus oral iron therapy for adults and children with chronic kidney disease.

Authors:  Emma L O'Lone; Elisabeth M Hodson; Ionut Nistor; Davide Bolignano; Angela C Webster; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2019-02-21

Review 5.  Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis.

Authors:  Zoe Tolkien; Lynne Stecher; Adrian P Mander; Dora I A Pereira; Jonathan J Powell
Journal:  PLoS One       Date:  2015-02-20       Impact factor: 3.240

6.  Myelodysplastic syndrome: the other cause of anemia in end-stage renal disease patients undergoing dialysis.

Authors:  Min-Yu Chang; Sheng-Fung Lin; Shih-Chi Wu; Wen-Chi Yang
Journal:  Sci Rep       Date:  2020-09-23       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.